The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

The preservative is in a small share of flu shots and has been studied for decades. Experts say it’s safe — despite Kennedy’s long opposition.

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Biological E partners with China’s Recbio to produce REC603 a 9-valent HPV vaccine in India The collaboration aims to expand ...

The strategies that the industry’s lobbyists use, or don’t deploy, matter as the Trump administration moves more decisively against the industry than during his first term— pulling vaccine ...

US Health Secretary Robert F Kennedy Jr fired all 17 members of a national vaccine advisory board, naming eight new members ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

The Trump administration’s new vaccine advisers endorsed this fall's flu vaccines late last week, but only those that don't ...

Biological E Ltd. has partnered with Jiangsu Recbio Technology to commercialize the latter's HPV9 vaccine, REC603, in India.

According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...